Structural Pathobiology – University of Copenhagen

Forward this page to a friend Resize Print Bookmark and Share

English > Research > Structural Pathobiology

Structural Pathobiology


Research in the section of pathobiology is focused primarily on the application of morphological techniques - scanning and transmission electron microscopy, confocal and fluorescence microscopy, immunohistochemistry and autoradiography - in the study of the pathophysiology of diseases in the GI tract, the lungs and the inner ear. 

Research areas

TFF-peptides

TFF peptides are small peptides co-secreted with mucus from mucus-producing cells throughout the body. By complex formation with mucus, they are decisive for the viskoelastic properties of the mucus and are believed to have pathophysiological significance in diseases, where the protective role of mucus is of importance for the development of disease.

The expression is upregulated in a number of diseases. Using animal models of diseases, we mainly focus on the role of the TFF peptides in the normal and diseased gastrointestinal tract and in the lungs and their possible application in the treatment of diseases in these organ systems.  

TFF peptides are very resistant to degradation by proteases and injected TFF is excreted intact in urine. High levels of endogenous TFF's are present in serum and urine and we investigate the diagnostic value of monitoring of disease activity through measuring their concentrations  in serum and urine.

GLP-2

GLP-2 is an intestinotrophic hormone produced by endocrine intestinal cells (L-cells) in the small and large intestine. It regulates the size and absorptive capacity of the intestinal system dependent on the intake of food. GLP2 analogues have a potential role in the treatment of short bowel syndrome, inflammatory bowel diseases and chemotherapy and irradiation induced mucositis. In experimental animal models we investigate the pathophysiological role of GLP-2 and the possible application for treatment of disorders of the GI tract.

Important Collaborations:

Ebba Nexø, Department of Clinical Biochemistry, University Hospital, Århus.
Lars Thim, Novo Nordisk A/S
Jens Juul Holst, Institute of Biomedical Institute, the Panum Institute.
Helle Krogh Johansen, department of Clinical Microbiology, Rigshospitalet